The estimated Net Worth of Richard L Md Lindstrom is at least $7.38 Миллион dollars as of 27 February 2024. Richard Lindstrom owns over 30,302 units of Harrow Health stock worth over $6,234,624 and over the last 10 years he sold HROW stock worth over $975,856. In addition, he makes $172,610 as Director at Harrow Health.
Richard has made over 10 trades of the Harrow Health stock since 2015, according to the Form 4 filled with the SEC. Most recently he exercised 30,302 units of HROW stock worth $266,658 on 27 February 2024.
The largest trade he's ever made was buying 100,000 units of Harrow Health stock on 19 December 2016 worth over $179,000. On average, Richard trades about 10,158 units every 110 days since 2014. As of 27 February 2024 he still owns at least 150,704 units of Harrow Health stock.
You can see the complete history of Richard Lindstrom stock trades at the bottom of the page.
Dr. Richard L. Lindstrom M.D. serves as Director of the Company. Dr. Lindstrom has served as a member of our Board of Directors since January 2015. Dr. Lindstrom is a founder, director and has been an attending surgeon at Minnesota Eye Consultants P.A., a provider of eye care services, since 1989. He has served as a researcher, teacher, inventor, writer, lecturer and highly acclaimed physician and surgeon in the ophthalmology field. He has also served as a member of the board of directors of TearLab Corporation since 2010 and Ocular Therapeutix, Inc. since 2012. Dr. Lindstrom is a medical advisor for several medical device and pharmaceutical manufacturers and serves on the boards of several other privately-held life sciences companies. Dr. Lindstrom previously served as president of the International Society of Refractive Surgery from 1993 to 1994, the International Intraocular Implant Society from 2002 to 2004, the International Refractive Surgery Club from 2002 to 2004, and the American Society of Cataract and Refractive Surgery (“ASCRS”) from 2007 to 2008. Dr. Lindstrom currently serves on the ASCRS Executive Committee and is a board member of the ASCRS Foundation. From 1980 to 1989, he served as a professor of ophthalmology at the University of Minnesota, where he is currently an adjunct professor emeritus. Dr. Lindstrom is also a Trustee of the University of Minnesota Foundation. Dr. Lindstrom holds a B.A. degree in Pre-Medical Studies, a B.S. degree in Medicine and an M.D. degree from the University of Minnesota. Dr. Lindstrom brings to the Board over 30 years of ophthalmology industry experience, as well extensive experience serving as a director of other companies.
As the Director of Harrow Health, the total compensation of Richard Lindstrom at Harrow Health is $172,610. There are 6 executives at Harrow Health getting paid more, with Mark Baum having the highest compensation of $1,377,010.
Richard Lindstrom is 72, he's been the Director of Harrow Health since 2017. There are no older and 10 younger executives at Harrow Health.
Richard's mailing address filed with the SEC is C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD, MA, 01730.
Over the last 6 years, insiders at Harrow Health have traded over $1,363,111 worth of Harrow Health stock and bought 1,487,560 units worth $12,882,479 . The most active insiders traders include Management Inc. Opaleye, Mark L Baum и Andrew R. Boll. On average, Harrow Health executives and independent directors trade stock every 29 days with the average trade being worth of $3,323,914. The most recent stock trade was executed by Management Inc. Opaleye on 25 April 2024, trading 20,000 units of HROW stock currently worth $199,400.
Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
Harrow Health executives and other stock owners filed with the SEC include: